The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models - Concepedia

Concepedia

Publication | Open Access

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

DOI Full Paper Access

111

Citations

33

References

2012

Year

Sarah V. Holt, Armelle Logié, Rajesh Odedra, Annabelle Heier, Simon P. Heaton, Denis Alférez, Barry R. Davies, Robert W. Wilkinson, Paul D. Smith

British Journal of Cancer

Abstract

The data presented suggests that MEK inhibition in combination with several standard chemotherapeutics or an Aurora B kinase inhibitor is a promising clinical strategy.

References

	Year	Citations

Page 1